Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
about
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta roleHistorical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer.Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapySpotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.Beyond platinum treatment for NSCLC: what does the future hold?Recent developments in the use of immunotherapy in non-small cell lung cancer.A novel multikinase inhibitor R8 exhibits potent inhibition on cancer cells through both apoptosis and autophagic cell death.Lentivirus-mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro.Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer.Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
P2860
Q26769734-8A91B362-979C-4977-87FE-4E0B52E0CB32Q37598057-0224632B-DA8B-4136-9CA2-8CB9709DED99Q37666880-4AFDD0EC-94AB-4AED-A55D-2F2270CCD7D2Q38598893-F774AF3C-5565-4BE9-89D8-02830A3966B8Q38663460-D667A827-78F0-4A96-9079-43552CA76F1AQ38765001-21A2FA14-C8E1-4400-9CC4-1B12B233885EQ38826419-84144145-2CA3-46FE-9479-36518733EFC6Q44869860-CE8A59D6-554A-4309-B8FE-8F6F6C65BE6AQ47257112-48D957D5-AAC8-4B50-A82E-BFE17BA750EBQ47861831-33A84F33-C014-4A1B-9FB7-B361A56E0BD7Q49188022-51620C28-ECE4-4A1D-833E-3B915A3F722CQ52584335-11BA58E8-B9D2-4532-AA21-B1D50D87566CQ54959395-6A1B0822-DE60-4FF7-A591-80186250F192Q57069991-547CF78C-46C4-49A1-88CE-51F27B7C7418
P2860
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Strategies to overcome resista ...... in non-small-cell lung cancer.
@en
type
label
Strategies to overcome resista ...... in non-small-cell lung cancer.
@en
prefLabel
Strategies to overcome resista ...... in non-small-cell lung cancer.
@en
P2860
P1476
Strategies to overcome resista ...... in non-small-cell lung cancer.
@en
P2093
Mariacarmela Santarpia
P2860
P304
P356
10.1586/17512433.2015.1055252
P407
P577
2015-06-11T00:00:00Z